Last reviewed · How we verify
Budesonide 200 µg plus formoterol 6 µg DPI
Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.
Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Budesonide 200 µg plus formoterol 6 µg DPI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide is an inhaled corticosteroid that suppresses inflammatory mediators and immune responses in the airways. Formoterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation. The combination provides both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: